Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of March 2025, with the specific transaction date being March 28, 2025. The filing details a share repurchase executed under a non-discretionary agreement with Citigroup Global Markets Limited.
Key Financial Metrics
The filing focuses exclusively on capital allocation via share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased (March 28, 2025): 834,200 ordinary shares.
- Price Range: Lowest price paid was 1,478.00 GBp; highest price paid was 1,491.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,485.54 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: 186,470,590 ordinary shares (post-transaction).
- Shares in Issue: 4,128,751,142 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,128,751,142.
Material Changes and Program Status
The purchase on March 28, 2025, was part of an existing buyback programme initiated via a non-discretionary agreement on February 24, 2025. Since the start of this agreement, GSK has purchased an aggregate of 17,400,287 ordinary shares. The filing does not provide comparative data against prior periods for operational performance, as the document is limited to the disclosure of the specific share transaction.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of the share purchase and the status of the buyback programme. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being detailed in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F. No specific guidance on future earnings or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the current buyback programme (17,400,287 since Feb 24, 2025) against the total programme authorization.
- Confirm the updated share count in issue (4,128,751,142) for calculating ownership percentages under Disclosure Guidance and Transparency Rules.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for the specific risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the remaining capacity of the buyback programme.